Bahuleyan, BijiMenon, GirishNair, SureshRao, B. R. M.Easwer, H. V.Krishna, Kumar2012-12-042012-12-042009JOURNAL OF CLINICAL NEUROSCIENCE. 16; 11; 1421-1424http://dx.doi.org/10.1016/j.jocn.2009.03.024http://www.ncbi.nlm.nih.gov/pubmed/19699096https://dspace.sctimst.ac.in/handle/123456789/800Cystic prolactinomas are considered not amenable to dopamine agonist therapy. We present the results of dopamine agonist therapy in six patients with cystic prolactinomas. The inclusion criteria of patients were: (i) cystic macroadenomas with the cyst occupying more than 50% of the turnout volume: (ii) a serum prolactin value more than 150 ng/mL. All patients were males with a mean age of 35 years. The clinical presentations were erectile dysfunction in 66.6%, Visual deficits in 50% and headache in 50% of patients. All patients were treated with bromocriptine only except one who was treated with both bromocriptine and cabergoline. The mean duration of follow up was 57.1 months. At the final follow-up 50% of patients had hormonal Cure, 50% had radiological cure and 50% had reduction in the size of the turnout. Hence, it is appropriate to consider dopamine agonist therapy in patients with cystic prolactinomas before considering surgery. (C) 2009 Elsevier Ltd. All rights reserved.Neurosurgery